drugset / Trial / NCT04539444
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
Phase 2
Completed
18 enrolled
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2022-09-30
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/22 CART | Cell therapy | 5e+06 cells/kg | — |
| Subject | CD19/22 CART | Cell therapy | 2e+07 cells/kg | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | — |